Role of procalcitonin levels on COVID-19 patients at Siti Fatimah hospital south Sumatera

Authors

  • Nurhayati Health Polytechnic, Ministry of Health, Department of Medical Laboratory Technology, Palembang, Indonesia
  • Asrori Health Polytechnic, Ministry of Health, Department of Medical Laboratory Technology, Palembang, Indonesia
  • Erwin Edyansyah Health Polytechnic, Ministry of Health, Department of Medical Laboratory Technology, Palembang, Indonesia https://orcid.org/0000-0002-0744-6262
  • Abdul Mutholib Health Polytechnic, Ministry of Health, Department of Medical Laboratory Technology, Palembang, Indonesia
  • Herry Hermansyah Health Polytechnic, Ministry of Health, Department of Medical Laboratory Technology, Palembang, Indonesia
  • Afifah Irham Health Polytechnic, Ministry of Health, Department of Medical Laboratory Technology, Palembang, Indonesia

DOI:

https://doi.org/10.18203/2320-6012.ijrms20231767

Keywords:

COVID-19, PCT, Procalcitonin

Abstract

Background: COVID-19 is a systemic disease that affects a broad spectrum of tissues and cells. Infected patients experience a wide variety of clinical signs, ranging from mild clinical signs to bilateral interstitial pneumonia. COVID-19 patients who also experience acute respiratory distress syndrome can result in multi-organ failure without comorbidities. Procalcitonin (PCT) also indicates severity and prognosis to reduce mortality.

Method: The research method is descriptive with a cross-sectional approach. The research was conducted at the Siti Fatimah hospital in South Sumatra province in February to May 2022. The sample for this research was the results of a PCT examination in 2021 totaling 66 people. The method for examining PCT levels uses the enzyme-linked method with serum or plasma samples.

Results: Obtained PCT levels showed that there was a low risk of PCT levels (≥0.05-<0.5) in 26 patients (39.4%), severe risk of PCT levels (≥0.5-<2) in 15 patients (22 .7%) and high risk of PCT levels (≥2) in 25 patients (37.9%). Based on mortality status, high levels were obtained in 43 patients with a low-risk living category in 21 patients. Based on the history of the disease, high levels were obtained in 41 patients with a history of high-risk disease in 18 patients. Based on the category of treatment in the inpatient room, high levels were obtained in 37 patients treated in the non-ICU room, resulting in low-risk PCT levels in 17 patients.

Conclusions: There is a 39.4% PCT level (≥0.05-<0.5) which indicates low risk is more common in COVID-19 patients than severe risk and high risk.

References

Susilo A, Rumende CM, Pitoyo CW, Santoso, Yulianti M, Herikurniawan, et al. Coronavirus Disease 2019: Tinjauan Literatur Terkini. J Penyakit Dalam Indonesia. 2020;7(1):45-67.

Prokalsitonin SB. D-dimer dan Ferritin sebagai Prediktor Perburukan COVID-19. CDK. 2021;48(11):357-60.

Liu ZM, Li JP, Wang SP, Chen DY, Zeng W, Chen SC, et al. Association of Procalcitonin Levels with the Progression and Prognosis of Hospitalized Patients with COVID-19. Int J Med Sci. 2020;17(16):2468-76.

Mus R, Thaslifa T, Abbas M, Sunaidi Y. Studi Literatur: Tinjauan Pemeriksaan Laboratorium pada Pasien COVID-19. J Kesehatan Vokasional. 2020;5(4):242.

Seran A, Hidayat LL. Pedoman Etika Penelitian Unika Atma Jaya. 2017;1-86.

Hu R, Han C, Shiyao YM, Chen X. Procalcitonin Levels in COVID-19 Patients Elsevier Enhanced Reader. Int J Antimicrobial Agents. 2020;56(2).

Ticinesi A, Nouvenne A, Prati B, Guida L, Parise A, Cerundolo N, et al. The Clinical Significance of Procalcitonin Elevation in Patients over 75 Years Old Admitted for COVID-19 Pneumonia. Hindawi Mediators of Inflammation. 2021;2021.

Abadi MSS, Taheri E, Raesi A, Arjmand MH, Kheirii S, Shahinfard N, et al. Procalcitonin as a Prognostic Factor in Patients with COVID-19 in Southwestern Iran. Infect Disord Drug Targets. 2022;22(3).

Antos A, Kwong ML, Balmorez T, Villanueva A, Dan Murakami S. Unusually high risks of COVID-19 mortality with age-related comorbidities: An adjusted meta-analysis method to improve the risk assessment of mortality using the comorbid mortality data. Infectious Disease Rep. 2021;13(3):700-11.

Zhang JJ, Cao YY, Tan G, Dong X, Wang BC, Lin J, et al. Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients. Allergy. 202176(2):533-50.

Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127.

Zhang, LF, Zhang, XH. Serum sTREM-1, PCT, CRP, Lac as biomarkers for death risk within 28 days in patients with severe sepsis, Open Life Sci. 2018;13:42-7.

Rodríguez A, Reyes LF, Monclou J, Suberviola B, Bodí M, Sirgo G, et al. Relationship between acute kidney injury and serum procalcitonin (PCT) concentration in critically ill patients with influenza infection. Med Intensiva. 2018;42:399-408.

Sayah W, Berkane I, Guermache I, Sabri M, Lakhal FZ, Rahali SY, et al. Interleukin-6, procalcitonin and neutrophil-to-lymphocyte ratio: Potential immune-inflammatory parameters to identify severe and fatal forms of COVID-19. Cytokine. 2021;141.

Tang J, Lin J, Zhang E, Zhong M, Luo Y, Fu Y, et al. Serum IL-6 and procalcitonin are two promising novel biomarkers for evaluating the severity of COVID-19 patients. Medicine. 2021;100:22.

Kamat IS, Ramachandran V, Eswaran H, Gufey D, Musher DM. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2020;70:538-42.

Twe CW, Khoo DKY, Law KB, Sabreena N, Sathasivan S, Lim KC, et al. The role of procalcitonin in predicting risk of mechanical ventilation and mortality among moderate to severe COVID-19 patients. BMC Infect Dis. 2022;22:378.

Downloads

Published

2023-06-05

How to Cite

Nurhayati, Asrori, Edyansyah, E., Mutholib, A., Hermansyah, H., & Irham, A. (2023). Role of procalcitonin levels on COVID-19 patients at Siti Fatimah hospital south Sumatera. International Journal of Research in Medical Sciences, 11(7), 2347–2352. https://doi.org/10.18203/2320-6012.ijrms20231767

Issue

Section

Original Research Articles